1551. Deputy Brian Stanley asked the Minister for Health further to Parliamentary Question No. 787 of 20 May 2025, around the reimbursement list scheme, the answer states that liraglutide (saxenda) is the only product currently approved under community drug schemes GMS/DPS for weight management, to clarify the criteria for use; if a person needs to be in diagnosis of prediabetes or can other factors such as high cardiovascular disease, hypertension or sleep apnoea qualify a patient for this drug therapy; and if she will make a statement on the matter. [30151/25]

Summary

1551. Deputy Brian Stanley asked the Minister for Health further to Parliamentary Question No. 787 of 20 May 2025, around the reimbursement list scheme, the answer states that liraglutide (saxenda) is the only product currently approved under community drug schemes GMS/DPS for weight management, to clarify the criteria for use; if a person needs to be in diagnosis of prediabetes or can other factors such as high cardiovascular disease, hypertension or sleep apnoea qualify a patient for this drug therapy; and if she will make a statement on the matter. [30151/25]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products

  xml · EN · 10 June 2025

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.